PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.
about
PEGylated Adenoviruses: From Mice to MonkeysExcess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signalingFrom unwitnessed fatality to witnessed rescue: Pharmacologic intervention in sudden unexpected death in epilepsyAutoimmune dysregulation and purine metabolism in adenosine deaminase deficiency.High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments.Next generation delivery system for proteins and genes of therapeutic purpose: why and how?Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapismRole of adenosine signaling in penile erection and erectile disorders.Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.A2B adenosine receptor-mediated induction of IL-6 promotes CKD.Development of a novel DDS for site-specific PEGylated proteins.Molecular defects in T- and B-cell primary immunodeficiency diseases.Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients.Pharmacokinetic consequences of pegylation.Detrimental effects of adenosine signaling in sickle cell disease.PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.Development of novel drug delivery systems using phage display technology for clinical application of protein drugsElevated ecto-5'-nucleotidase-mediated increased renal adenosine signaling via A2B adenosine receptor contributes to chronic hypertension.Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.Delivery of therapeutic proteins.Adenosine signaling in normal and sickle erythrocytes and beyond.Inborn errors of metabolism underlying primary immunodeficiencies.Erythrocyte-mediated delivery of recombinant enzymes.Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles.
P2860
Q24635276-F400D48C-0009-4621-8291-CD5AE0AAACCBQ24655020-3E865A98-BBCC-43BE-A5AC-E0D55C2107A7Q26770025-C005079B-1F71-4050-9EB4-07843EAF7E20Q33403252-27859528-14BD-427A-BC14-04AF8BA19FE0Q33784122-57A80140-5551-40CE-8933-7AA72769A3B1Q34003800-98AEEA30-3EDC-48E2-A3B0-91ABDBB8D37AQ34005421-23BD0970-EDE5-49AE-92C9-191285F99AB4Q34020025-18DD6191-5CD1-4FFB-9228-F58B2CF88190Q34747443-5F153454-D2E4-4655-80C4-F89DAFD09CC1Q34870775-4D0306E5-C44E-4201-A79C-1C4B37AD9C35Q35040200-322A9AA5-AF3C-49FE-BE33-521008F78897Q36302334-49F4304A-78F8-4681-9237-9687D5EA7E95Q36528787-2E67C451-9D7D-457A-B101-4C5C50ADF0D5Q36604526-88D6286D-1BE7-46E3-8BAF-DE1A6623AFD3Q36818005-850F0404-DA08-4BFB-8913-10C2CC2685C7Q36940229-C4A75219-19C3-4E31-8A55-5D0D873FBC75Q37182935-552559AD-91C4-47BA-A0C1-47985A2B8191Q37198453-FDF7CB14-E89B-4C0B-A57A-88203EB66B02Q37454990-D744C48D-8057-4898-80ED-30E208721B94Q37586932-D62EE9FC-E67C-4C76-AF53-67FAA802CE09Q37664729-12E16C59-F478-4D51-8642-86DC0366575DQ37668486-C5E9EFB1-68EB-436A-B8C3-199F4BC9A36DQ38013492-3F4A595B-C8EF-4D94-B190-171C5AF0BFA3Q38235840-8B09A34D-BEDE-4C5A-8B9B-39F4BB6C4D42Q38793040-60D1C319-C523-4C49-A8D2-2D92365393C6Q42602801-8DAEAF25-5B35-44CD-8693-5F630E00C431
P2860
PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
PEG-ADA replacement therapy fo ...... cy: an update after 8.5 years.
@en
PEG-ADA replacement therapy fo ...... cy: an update after 8.5 years.
@nl
type
label
PEG-ADA replacement therapy fo ...... cy: an update after 8.5 years.
@en
PEG-ADA replacement therapy fo ...... cy: an update after 8.5 years.
@nl
prefLabel
PEG-ADA replacement therapy fo ...... cy: an update after 8.5 years.
@en
PEG-ADA replacement therapy fo ...... cy: an update after 8.5 years.
@nl
P1476
PEG-ADA replacement therapy fo ...... cy: an update after 8.5 years.
@en
P2093
M S Hershfield
P304
P356
10.1016/S0090-1229(95)90306-2
P433
P577
1995-09-01T00:00:00Z